FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021198987> ?p ?o ?g. }

• W2021198987 endingPage "1188" @default.
• W2021198987 startingPage "1182" @default.
• W2021198987 abstract "The aim of this study was to systematically assess the effectiveness and safety of the addition of antiangiogenic agents to docetaxel-based chemotherapy for the treatment of castration-resistant prostate cancer. Computerized electronic databases, including Embase, PubMed and The Cochrane Library were searched for randomized controlled trials (RCTs) on the comparison between docetaxel-based therapy with and without antiangiogenic agents for the treatment of prostate cancer. The search time limit was from the building of the database until July 18, 2013. Following extracting information and conducting a methodological quality evaluation for study inclusion based on inclusion and exclusion criteria, RevMan 5.2 and Stata 12.0 software were used to perform a meta-analysis and the Jadad scale was used for evaluation of study quality. A total of 9 RCTs and 4,681 patients were included in this meta-analysis. The comparison between docetaxel-based therapy with and without antiangiogenic agents revealed no statistically significant differences regarding prostate-specific antigen response rate [risk ratio (RR)=0.99, 95% confidence interval (CI): 0.87-1.12, P=0.84], overall survival (OS) [hazard ratio (HR)=0.97, 95%CI: 0.91-1.05)] and progression-free survival (PFS) (HR=0.99, 95%CI: 0.83-1.18); however, the incidence of treatment-related mortality was higher in the docetaxel-based therapy with antiangiogenic agents group (RR=1.95, 95%CI: 1.23-3.11, P=0.005), whereas the incidence of thrombus formation was higher in the docetaxel-based therapy without antiangiogenic agents group (RR=0.57, 95%CI: 0.41-0.80, P=0.001). In conclusion, our findings indicated that docetaxel combined with antiangiogenic agents did not increase the OS or the PFS of the patients with castration-resistant prostate cancer, whereas it may increase the risk of treatment-related mortality. However, further RCTs with larger, high-quality patient samples are required to verify these findings." @default.
• W2021198987 created "2016-06-24" @default.
• W2021198987 creator A5014528965 @default.
• W2021198987 creator A5030930209 @default.
• W2021198987 creator A5051475064 @default.
• W2021198987 creator A5058342595 @default.
• W2021198987 creator A5068479212 @default.
• W2021198987 creator A5080386051 @default.
• W2021198987 creator A5091359667 @default.
• W2021198987 date "2014-08-26" @default.
• W2021198987 modified "2023-10-01" @default.
• W2021198987 title "Docetaxel-based therapy with and without antiangiogenic agents as first-line chemotherapy for castration-resistant prostate cancer: A meta-analysis of nine randomized controlled trials" @default.
• W2021198987 cites W1893347245 @default.
• W2021198987 cites W1972912578 @default.
• W2021198987 cites W1986215651 @default.
• W2021198987 cites W2005090101 @default.
• W2021198987 cites W2023375628 @default.
• W2021198987 cites W2075438984 @default.
• W2021198987 cites W2100304113 @default.
• W2021198987 cites W2103059478 @default.
• W2021198987 cites W2113046540 @default.
• W2021198987 cites W2118628551 @default.
• W2021198987 cites W2120292596 @default.
• W2021198987 cites W2121800941 @default.
• W2021198987 cites W2144813855 @default.
• W2021198987 cites W2153140330 @default.
• W2021198987 cites W2160129915 @default.
• W2021198987 cites W2161817637 @default.
• W2021198987 cites W2165088640 @default.
• W2021198987 cites W2165542862 @default.
• W2021198987 cites W2167074319 @default.
• W2021198987 cites W2169700609 @default.
• W2021198987 cites W2589309657 @default.
• W2021198987 cites W2589328836 @default.
• W2021198987 doi "https://doi.org/10.3892/mco.2014.404" @default.
• W2021198987 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4179809" @default.
• W2021198987 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25279220" @default.
• W2021198987 hasPublicationYear "2014" @default.
• W2021198987 type Work @default.
• W2021198987 sameAs 2021198987 @default.
• W2021198987 citedByCount "5" @default.
• W2021198987 countsByYear W20211989872017 @default.
• W2021198987 countsByYear W20211989872019 @default.
• W2021198987 countsByYear W20211989872021 @default.
• W2021198987 countsByYear W20211989872022 @default.
• W2021198987 crossrefType "journal-article" @default.
• W2021198987 hasAuthorship W2021198987A5014528965 @default.
• W2021198987 hasAuthorship W2021198987A5030930209 @default.
• W2021198987 hasAuthorship W2021198987A5051475064 @default.
• W2021198987 hasAuthorship W2021198987A5058342595 @default.
• W2021198987 hasAuthorship W2021198987A5068479212 @default.
• W2021198987 hasAuthorship W2021198987A5080386051 @default.
• W2021198987 hasAuthorship W2021198987A5091359667 @default.
• W2021198987 hasBestOaLocation W20211989871 @default.
• W2021198987 hasConcept C121608353 @default.
• W2021198987 hasConcept C126322002 @default.
• W2021198987 hasConcept C136524200 @default.
• W2021198987 hasConcept C143998085 @default.
• W2021198987 hasConcept C168563851 @default.
• W2021198987 hasConcept C207103383 @default.
• W2021198987 hasConcept C2776478404 @default.
• W2021198987 hasConcept C2776694085 @default.
• W2021198987 hasConcept C2777802072 @default.
• W2021198987 hasConcept C2777899217 @default.
• W2021198987 hasConcept C2778971682 @default.
• W2021198987 hasConcept C2780192828 @default.
• W2021198987 hasConcept C2781190966 @default.
• W2021198987 hasConcept C44249647 @default.
• W2021198987 hasConcept C71924100 @default.
• W2021198987 hasConcept C95190672 @default.
• W2021198987 hasConceptScore W2021198987C121608353 @default.
• W2021198987 hasConceptScore W2021198987C126322002 @default.
• W2021198987 hasConceptScore W2021198987C136524200 @default.
• W2021198987 hasConceptScore W2021198987C143998085 @default.
• W2021198987 hasConceptScore W2021198987C168563851 @default.
• W2021198987 hasConceptScore W2021198987C207103383 @default.
• W2021198987 hasConceptScore W2021198987C2776478404 @default.
• W2021198987 hasConceptScore W2021198987C2776694085 @default.
• W2021198987 hasConceptScore W2021198987C2777802072 @default.
• W2021198987 hasConceptScore W2021198987C2777899217 @default.
• W2021198987 hasConceptScore W2021198987C2778971682 @default.
• W2021198987 hasConceptScore W2021198987C2780192828 @default.
• W2021198987 hasConceptScore W2021198987C2781190966 @default.
• W2021198987 hasConceptScore W2021198987C44249647 @default.
• W2021198987 hasConceptScore W2021198987C71924100 @default.
• W2021198987 hasConceptScore W2021198987C95190672 @default.
• W2021198987 hasIssue "6" @default.
• W2021198987 hasLocation W20211989871 @default.
• W2021198987 hasLocation W20211989872 @default.
• W2021198987 hasLocation W20211989873 @default.
• W2021198987 hasLocation W20211989874 @default.
• W2021198987 hasOpenAccess W2021198987 @default.
• W2021198987 hasPrimaryLocation W20211989871 @default.
• W2021198987 hasRelatedWork W122177069 @default.
• W2021198987 hasRelatedWork W1543388821 @default.
• W2021198987 hasRelatedWork W2094570582 @default.
• W2021198987 hasRelatedWork W2135620818 @default.
• W2021198987 hasRelatedWork W2299690226 @default.

• next